Drugs / Inactivated Poliomyelitis Vaccine
Trials 3
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT01048190 | Aug 2008 → Mar 2009 | poliomyelitis | Chinese Academy of Medical Sciences | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT00258843 | Nov 2005 → Feb 2006 | poliomyelitis | Sanofi Pasteur, a Sanofi Company | Completed | No outcome recorded |
| Phase 41 trial · 1 met primary | ||||||
| Phase 4 | NCT01475539 | Nov 2011 → May 2013 | poliomyelitis | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
| Comparator or background therapy1 trial | ||||||
| Phase 3 | NCT04429295 Comparator | Jun 2020 → Feb 2021 | Rotavirus infection, diphtheria, haemophilus meningitis, hepatitis B virus infection +3 | Sanofi Pasteur, a Sanofi Company | Completed | Met primary |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 4 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Inactivated Poliomyelitis Vaccine | “Inactivated Poliomyelitis Vaccine (IPV)-(Oral Poliomyelitis Vaccine) (OPV)-OPV (Sequential 1)” NCT01475539 ↗ |
| Modality | Vaccine | “Biological: Inactivated Poliomyelitis vaccine” NCT00258843 ↗ |
| Route | Intramuscular | “0.5 mL, intramuscular (IM)” NCT00258843 ↗ |